Overview
| Name | TerraBind · aliases: TerraBind, EMMI Predict |
|---|---|
| Full name | The paper gives no expanded name; the commercial product name is listed as an alias |
| Ambiguous names (not auto-linked) | None |
| Family | Not a family entry. Only one version (arXiv v1); no family members |
| Organization | Terray Therapeutics |
| Organization type | AI-native biotech |
| Country | United States |
| Model class | Co-folding / affinity prediction (diffusion-free) |
| Domain | Small molecules (also: Structure & co-folding) |
| First release | · paper revision Basis: arXiv v1 submitted (the only version) Note: The company press release came four days later and is not used as first-release evidence source |
| Other milestones | |
| Latest update | † partly verified · no later event Basis: Commercial product launch press release The latest sourced event is a press release for the commercial product launch; no later version, code or weights were found and the arXiv record is still v1. The event is promotional, not a new model version Note: Must display as unverified: a press release is not a model version event source The most recent sourced event, not a claim that nothing changed since. |
| Status | Product only, no public artifact · No public code or weights; offered as a commercial product |
| Openness | Code: Closed Weights: Closed The paper gives no code or weights link, so it is treated as not open; it is offered under a commercial product name |
| Benchmarks reported | 2 counted (modified protocol 1, retrospective 1) |
| Wet-lab validation | 1 recorded campaign |
| Unverified fields | † latest_update, release_milestones.official_announcement, background.funding, background.products_partnerships |
| As of | 2026-11-16 |
What it does
Uses a smaller pairformer trunk with a diffusion-free optimisation scheme to output structure and affinity directly, plus a per-inference uncertainty estimate; parameter comparisons hold only at the trunk level and must not be set against the baseline's full model size. Nesso-1 explicitly follows this slimming route, while AQAffinity builds on another open co-folding model; the comparison baseline is Boltz-2.
Benchmarks reported
Every row is one pairing from the survey's relation file; a score belongs to the benchmark page's ranking, where it is shown with metric, eval set, source type and date. 2 of 2 pairings are counted.
| Benchmark | Relation | Eval set / protocol | Source type | Note and evidence |
|---|---|---|---|---|
| 05 PoseBusters | Developer report, modified protocol | — | Self-reported | Merged into a chart with two other benchmarks; no number for this benchmark alone †partly verified · evidence |
| 01 CASP | Retrospective dataset use | — | Third-party | Retrospective CASP16 affinity evaluation · evidence |
Other evaluations (outside the 44)
- Two structural sets (off-site) (Public benchmark not among the 44) Self-reported: Merged into the same chart with two other public structural sets; pose accuracy self-reported as comparable to an earlier baseline
- Affinity evaluation on 18 internal targets (Own task set) Self-reported: Per-target correlation comparison on developer-owned data that outsiders cannot recompute
- End-to-end speed comparison (Comparison against baselines only) Self-reported: A speed-up measured at a fixed GPU, token length and sample count per complex; the conclusion depends on that setup
- Role of a high-throughput activity dataset (Comparison against baselines only) Self-reported: In the paper that dataset is only a source of affinity training data, not a reported evaluation, so it cannot be set against the baseline's same-named result
Developers report: a much smaller trunk with diffusion-free optimisation matches an earlier baseline's pose accuracy, runs more than an order of magnitude faster end to end, and correlates better than the comparator on a released affinity set and on internal targets.
Independent evidence: No independent evidence found. With no code or weights, no third-party evaluation was found; the claimed advantage partly rests on developer-owned target data
Training data
Group in Figure 7: Public data + wet lab for validation only.
| Class | Value | Detail |
|---|---|---|
| a. Public databases | Yes | Public structure and predicted-structure databases, public complex sets, with affinity from several public activity databases plus around a million synthetic decoys source |
| b. Private or licensed data | No | None for the base model; nine proprietary crystal structures across two targets were used only in a separate fine-tuning experiment source |
| c. Own wet-lab data used for training | No | The paper states the base model uses public data only source |
| d. Wet lab used only for validation | Yes | Existing biochemical and cell assay data for 18 internal targets used for evaluation only, not new wet-lab work source |
Wet-lab validation
Every rate carries its numerator and denominator. Claims that could not be verified are shown as unverified, without numbers; different paper versions are separate entries.
Denominator basis: 18 internal targets with more than 95 IC50 points each; nine proprietary crystals across two targets used only in a fine-tuning experiment
The data come from ongoing projects, are uncurated and span several chemical series; the total compound count is not given
Executor: The data belong to the developer; not an independent evaluation and not a new wet-lab campaign
Background
- Organization: A US AI small-molecule drug-discovery company founded in 2018 (headquartered in California; the paper's address differs from the city in earlier coverage), running its own pipeline alongside pharma collaborations; its platform includes a data engine the company says produces a billion-scale set of small-molecule binding measurements with ultra-miniaturised chips.
- Funding: A $60M Series A in 2022 led by one venture firm; a $120M Series B announced 2024-10-17 co-led by a new investor and a chipmaker's venture arm with several other participants; the company reports over $200M raised in total.
- Products and partnerships: Collaborations include a large pharma company (2023-12, multi-target), a life-science research company, a transcription-factor-focused biotech (2024-10) and another large pharma company (2024-12); public materials mention upfronts, milestones and tiered royalties with no amounts disclosed.
- Related models: Boltz-2, Nesso-1, AQAffinity
Reading notes
- A substantial part of the claimed affinity advantage comes from developer-owned targets that outsiders cannot reproduce.
- The speed claim depends on a specific hardware and sampling setup and need not hold elsewhere.
- PoseBusters appears only in a merged bar chart with no standalone value, so it cannot be compared with same-named figures elsewhere.
- Other teams are following the diffusion-free slimming route, suggesting affinity tasks may not need full atom-level diffusion.
Caveats
- The latest update is a company press release (promotional), not a model version, and must display as unverified.
- No public code or weights, so the results cannot be independently recomputed.
- Parameter comparisons hold only at the trunk level.
- The CASP entry is retrospective dataset use and does not count toward reported benchmarks.
Sources
- arXiv 2602.07735 v1 (preprint)
- Paper full text (HTML) (preprint)
- Commercial launch press release (press)
- Company product page (official site)
Corrections
2 corrections
| Field | Was | Now | Basis | Found |
|---|---|---|---|---|
| latest_update | 2026-02-12 recorded as a model update | Same date, but it is a press release and the kind is no later sourced event; must be marked unverified | source | 2026-11-16 |
| other_evaluations | Reports evaluation results on a high-throughput activity dataset | In the paper this dataset is only a training-data source, with no evaluation results | source | 2026-11-16 |
Part of the AI for Bio benchmarks survey · all 112 models · open in the explorer. Record as of 2026-11-16.